Evidence map›Paper›PMID 34532923›Full record

ArticleAddiction biology2022

Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA).

Gianni Testino, Teo Vignoli, Valentino Patussi, Pierluigi Allosio, Maria Francesca Amendola, Sarino Aricò, Aniello Baselice, Patrizia Balbinot, Vito Campanile, Tiziana Fanucchi and 13 more

Open access · hybridAbstract readConsensus Statement
In one paragraph

Article in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 7 countries.

Gianni TestinoUnit of Addiction and Hepatology, Regional Centre on Alcohol, ASL3 San Martino Hospital, Genoa, Italy.
Teo VignoliUnit of Addiction Treatment, Lugo (Ravenna), Italy.
Valentino PatussiRegional Centre on Alcohol, Careggi Hospital, Florence, Italy.
Pierluigi AllosioAlcohol Unit, Torino, Italy.
Maria Francesca AmendolaAlcohol Unit, Cosenza, Italy.
Sarino AricòGastroenterology Unit, Mauriziano Hospital, Torino, Italy.
Aniello BaseliceAlcohol Unit, Salerno, Italy.
Patrizia BalbinotUnit of Addiction and Hepatology, Regional Centre on Alcohol, ASL3 San Martino Hospital, Genoa, Italy.
Vito CampanileAlcohol Unit, Bari, Italy.
Tiziana FanucchiRegional Centre on Alcohol, Careggi Hospital, Florence, Italy.
Livia MacciòAlcoholo Unit, Savona, Italy.
Cristina MeneguzziAlcohol Unit, Pordenone, Italy.
Davide MioniNursing Home Parco dei Tigli, Teolo, Italy.
Michele ParisiAlcohol Unit, Nicosia, Italy.
Doda RenzettiDepartment of Internal Medicine, Mater Dei Hospital, Bari, Italy.
Raffaella RossinAlcohol Unit, Milan, Italy.
Claudia GandinNational Observatory on Alcohol, National Institute of Health, Rome, Italy.
Luigi Carlo BottaroLocal Health Service, Liguria, Italy.
Giacomo CaioCentre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Lisa LungaroCentre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Giorgio ZoliCentre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
Emanuele ScafatoNational Observatory on Alcohol, National Institute of Health, Rome, Italy.
Fabio CaputoCentre for the Study and Treatment of Alcohol-Related Diseases, Department of Translational Medicine, University of Ferrara, Ferrara, Italy.ORCID 0000-0002-8953-8338
University of Ferrara · ITAzienda Ospedaliero-Universitaria Careggi · ITInstitute of Alcohol Studies · GBIstituto Superiore di Sanità · ITMartin University · USAgenzia Regionale per la Protezione dell'ambiente ligure · ITAlcohol Research Group · USAlcon (Italy) · ITA. O. Ordine Mauriziano di Torino · ITAzienda Ospedaliera di Cosenza · ITAzienda Sanitaria Locale N. 2 Savonese · ITMater Dei Hospital · MTTactus Verslavingszorg · NLTorino e-district · ITUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) first emerged in China in November 2019. Most governments have responded to the COVID-19 pandemic by imposing a lockdown. Some evidence suggests that a period of isolation might have led to a spike in alcohol misuse, and in the case of patients with alcohol use disorder (AUD), social isolation can favour lapse and relapse. The aim of our position paper is to provide specialists in the alcohol addiction field, in psychopharmacology, gastroenterology and in internal medicine, with appropriate tools to better manage patients with AUD and COVID-19,considering some important topics: (a) the susceptibility of AUD patients to infection; (b) the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) the reorganization of the Centre for Alcohol Addiction Treatment for the management of AUD patients in the COVID-19 era (group activities, telemedicine, outpatients treatment, alcohol-related liver disease and liver transplantation, collecting samples); (d) AUD and SARS-CoV-2 vaccination. Telemedicine/telehealth will undoubtedly be useful/practical tools even though it remains at an elementary level; the contribution of the family and of caregivers in the management of AUD patients will play a significant role; the multidisciplinary intervention involving experts in the treatment of AUD with specialists in the treatment of COVID-19 disease will need implementation. Thus, the COVID-19 pandemic is rapidly leading addiction specialists towards a new governance scenario of AUD, which necessarily needs an in-depth reconsideration, focusing attention on a safe approach in combination with the efficacy of treatment.

Indexed as

Communicable Disease ControlAlcoholics AnonymousAlcoholismAmbulatory CareCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesDelivery of Health CareDisease SusceptibilityDrug InteractionsHumansImmunosuppression TherapyItalyLiver Cirrhosis, AlcoholicLiver TransplantationRecurrenceCOVID-19 Vaccinesalcohol use disorderCOVID-19 infectiondrug interactionsinfectionstelemedicine

Identifiers

PMID34532923
PMCPMC8646667
OpenAlexW3200244058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.